Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #65
mi
from
Skillman, NJ
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #65
mi
from
Skillman, NJ
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #7
mi
from
New York, NY
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #7
mi
from
New York, NY
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #41
mi
from
Clemmons, NC
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #41
mi
from
Clemmons, NC
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #45
mi
from
Raleigh, NC
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #45
mi
from
Raleigh, NC
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #31
mi
from
Cincinnati, OH
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #31
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #95
mi
from
Columbus, OH
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #95
mi
from
Columbus, OH
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #24
mi
from
Hilliard, OH
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #24
mi
from
Hilliard, OH
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #61
mi
from
Middleburg Heights, OH
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #61
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #73
mi
from
Toledo, OH
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #73
mi
from
Toledo, OH
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #14
mi
from
Edmond, OK
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #14
mi
from
Edmond, OK
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #15
mi
from
Oklahoma City, OK
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #15
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #37
mi
from
Eugene, OR
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #37
mi
from
Eugene, OR
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #40
mi
from
Medford, OR
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #40
mi
from
Medford, OR
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #58
mi
from
Portland, OR
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #58
mi
from
Portland, OR
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #26
mi
from
Warwick, RI
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #26
mi
from
Warwick, RI
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #69
mi
from
Greenville, SC
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #69
mi
from
Greenville, SC
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #22
mi
from
Spartanburg, SC
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #22
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #19
mi
from
Smyrna, TN
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #19
mi
from
Smyrna, TN
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #27
mi
from
Boerne, TX
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #27
mi
from
Boerne, TX
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #75
mi
from
Dallas, TX
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #75
mi
from
Dallas, TX
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #49
mi
from
El Paso, TX
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #49
mi
from
El Paso, TX
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #44
mi
from
Houston, TX
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #44
mi
from
Houston, TX
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #77
mi
from
Lewisville, TX
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #77
mi
from
Lewisville, TX
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #87
mi
from
Plano, TX
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #87
mi
from
Plano, TX
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #29
mi
from
San Antonio, TX
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #29
mi
from
San Antonio, TX
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #42
mi
from
West Jordan, UT
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #42
mi
from
West Jordan, UT
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #39
mi
from
South Burlington, VT
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #39
mi
from
South Burlington, VT
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #9
mi
from
Henrico, VA
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #9
mi
from
Henrico, VA
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #88
mi
from
Richmond, VA
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #88
mi
from
Richmond, VA
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #76
mi
from
Tacoma, WA
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #76
mi
from
Tacoma, WA
Click here to add this to my saved trials
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated:  1/19/2018
Roxane Laboratories Research Site #82
mi
from
Greenfield, WI
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Status: Enrolling
Updated: 1/19/2018
Roxane Laboratories Research Site #82
mi
from
Greenfield, WI
Click here to add this to my saved trials
Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 5 mg Chewable Tablets Under Fed Conditions
Status: Enrolling
Updated:  1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 5 mg Chewable Tablets Under Fed Conditions
Status: Enrolling
Updated: 1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Click here to add this to my saved trials
Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 5 mg Chewable Tablets Under Fasted Conditions
Status: Enrolling
Updated:  1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 5 mg Chewable Tablets Under Fasted Conditions
Status: Enrolling
Updated: 1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Click here to add this to my saved trials
Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 10 mg Tablets Under Fed Conditions
Status: Enrolling
Updated:  1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 10 mg Tablets Under Fed Conditions
Status: Enrolling
Updated: 1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Click here to add this to my saved trials
Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 10 mg Tablets Under Fasted Conditions
Status: Enrolling
Updated:  1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 10 mg Tablets Under Fasted Conditions
Status: Enrolling
Updated: 1/19/2018
PRACS Institute, Ltd.
mi
from
Fargo, ND
Click here to add this to my saved trials
Informed Consent Formats by Information Preference and Priority
Informed Consent Formats by Information Preference and Priority
Status: Enrolling
Updated:  1/24/2018
Carnegie Mellon University
mi
from
Pittsburgh, PA
Informed Consent Formats by Information Preference and Priority
Informed Consent Formats by Information Preference and Priority
Status: Enrolling
Updated: 1/24/2018
Carnegie Mellon University
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Supporting Asthma Management Behaviors in Aging Adults
Clinic-based vs. Home-based Support to Improve Care and Outcomes for Older Asthmatics
Status: Enrolling
Updated:  2/2/2018
Institute for Family Health
mi
from
New York, NY
Supporting Asthma Management Behaviors in Aging Adults
Clinic-based vs. Home-based Support to Improve Care and Outcomes for Older Asthmatics
Status: Enrolling
Updated: 2/2/2018
Institute for Family Health
mi
from
New York, NY
Click here to add this to my saved trials
Supporting Asthma Management Behaviors in Aging Adults
Clinic-based vs. Home-based Support to Improve Care and Outcomes for Older Asthmatics
Status: Enrolling
Updated:  2/2/2018
Mount Sinai-St. Luke's Roosevelt Hospital Center
mi
from
New York, NY
Supporting Asthma Management Behaviors in Aging Adults
Clinic-based vs. Home-based Support to Improve Care and Outcomes for Older Asthmatics
Status: Enrolling
Updated: 2/2/2018
Mount Sinai-St. Luke's Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Supporting Asthma Management Behaviors in Aging Adults
Clinic-based vs. Home-based Support to Improve Care and Outcomes for Older Asthmatics
Status: Enrolling
Updated:  2/2/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Supporting Asthma Management Behaviors in Aging Adults
Clinic-based vs. Home-based Support to Improve Care and Outcomes for Older Asthmatics
Status: Enrolling
Updated: 2/2/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN
Accelerating Implementation of Comparative Effectiveness Findings on Clinical and Delivery Systems by Leveraging AHRQ Networks
Status: Enrolling
Updated:  2/4/2018
Department of Family Medicine
mi
from
Charlotte, NC
Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN
Accelerating Implementation of Comparative Effectiveness Findings on Clinical and Delivery Systems by Leveraging AHRQ Networks
Status: Enrolling
Updated: 2/4/2018
Department of Family Medicine
mi
from
Charlotte, NC
Click here to add this to my saved trials
Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN
Accelerating Implementation of Comparative Effectiveness Findings on Clinical and Delivery Systems by Leveraging AHRQ Networks
Status: Enrolling
Updated:  2/4/2018
CMC Elizabeth Family Medicine
mi
from
Charlotte, NC
Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN
Accelerating Implementation of Comparative Effectiveness Findings on Clinical and Delivery Systems by Leveraging AHRQ Networks
Status: Enrolling
Updated: 2/4/2018
CMC Elizabeth Family Medicine
mi
from
Charlotte, NC
Click here to add this to my saved trials
Subcutaneous Immunotherapy for Mouse in Adults
A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)
Status: Enrolling
Updated:  2/5/2018
Children's National Health System
mi
from
Washington,
Subcutaneous Immunotherapy for Mouse in Adults
A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)
Status: Enrolling
Updated: 2/5/2018
Children's National Health System
mi
from
Washington,
Click here to add this to my saved trials
Subcutaneous Immunotherapy for Mouse in Adults
A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)
Status: Enrolling
Updated:  2/5/2018
Ann & Robert Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Subcutaneous Immunotherapy for Mouse in Adults
A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)
Status: Enrolling
Updated: 2/5/2018
Ann & Robert Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Subcutaneous Immunotherapy for Mouse in Adults
A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)
Status: Enrolling
Updated:  2/5/2018
Johns Hopkins Children's Center: Department of Allergy & Immunology
mi
from
Baltimore, MD
Subcutaneous Immunotherapy for Mouse in Adults
A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)
Status: Enrolling
Updated: 2/5/2018
Johns Hopkins Children's Center: Department of Allergy & Immunology
mi
from
Baltimore, MD
Click here to add this to my saved trials
Subcutaneous Immunotherapy for Mouse in Adults
A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)
Status: Enrolling
Updated:  2/5/2018
Henry Ford Health System: Division of Allergy and Immunology
mi
from
Detroit, MI
Subcutaneous Immunotherapy for Mouse in Adults
A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)
Status: Enrolling
Updated: 2/5/2018
Henry Ford Health System: Division of Allergy and Immunology
mi
from
Detroit, MI
Click here to add this to my saved trials
Asthma Controller Adherence After Hospitalization
Automated Adherence Feedback for High Risk Children With Asthma
Status: Enrolling
Updated:  2/7/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Asthma Controller Adherence After Hospitalization
Automated Adherence Feedback for High Risk Children With Asthma
Status: Enrolling
Updated: 2/7/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Iggy and the Inhalers: A Study to Assess the Impact of an Asthma Education Program in School Age Children
Iggy and the Inhalers: A Pilot Study to Assess the Impact of an Asthma Education Program in School Age Children
Status: Enrolling
Updated:  2/7/2018
Yacktman Pediatrics
mi
from
Park Ridge, IL
Iggy and the Inhalers: A Study to Assess the Impact of an Asthma Education Program in School Age Children
Iggy and the Inhalers: A Pilot Study to Assess the Impact of an Asthma Education Program in School Age Children
Status: Enrolling
Updated: 2/7/2018
Yacktman Pediatrics
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System
Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System
Status: Enrolling
Updated:  2/9/2018
Woodland Medical Center
mi
from
Woodland, CA
Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System
Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System
Status: Enrolling
Updated: 2/9/2018
Woodland Medical Center
mi
from
Woodland, CA
Click here to add this to my saved trials
An Observational Study of the Use and Safety of Xolair® During Pregnancy
The Xolair® Pregnancy Registry: An Observational Study of the Use and Safety of Xolair® (Omalizumab) During Pregnancy
Status: Enrolling
Updated:  2/12/2018
Ppd Development, Llc
mi
from
Morrisville, NC
An Observational Study of the Use and Safety of Xolair® During Pregnancy
The Xolair® Pregnancy Registry: An Observational Study of the Use and Safety of Xolair® (Omalizumab) During Pregnancy
Status: Enrolling
Updated: 2/12/2018
Ppd Development, Llc
mi
from
Morrisville, NC
Click here to add this to my saved trials
A Community Health Worker Home Intervention to Improve Pediatric Asthma Outcomes
A Randomized Controlled Trial of a Community Health Worker Home-Based Asthma Intervention
Status: Enrolling
Updated:  2/13/2018
Montefiore Medical Group- CHCC
mi
from
Bronx, NY
A Community Health Worker Home Intervention to Improve Pediatric Asthma Outcomes
A Randomized Controlled Trial of a Community Health Worker Home-Based Asthma Intervention
Status: Enrolling
Updated: 2/13/2018
Montefiore Medical Group- CHCC
mi
from
Bronx, NY
Click here to add this to my saved trials